Sunovion launches oral Parkinson’s treatment

Photo | Grant Welker Sunovion's Marlborough headquarters

Write a Comment

Marlborough pharmaceutical company Sunovion announced on Monday the commercial launch of KYNMOBI, a drug aimed at treating OFF episodes in patients with Parkinson’s disease.

KYNMOBI is a film that dissolves under patients’ tongues to treat OFF symptoms, according to a press release from Sunovion. OFF episodes is the term for when Parkinson's patients experience symptoms like tremor or difficulty walking.

“People living with Parkinson’s disease can potentially spend hours each day navigating disruptions caused by OFF episodes, which may result in reduced motor function and present challenges performing daily activities,” said Thomas Gibbs, senior vice president and chief commercial officer at Sunovion, in a statement.

According to Gibbs, those episodes can make otherwise basic daily tasks nearly impossible.

“Reduced mobility associated with OFF episodes can be one of the most troubling and burdensome aspects for people living with Parkinson’s disease,” said Dr. Stuart Isaacson, director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton, in a statement. “This is intensified as Parkinson’s disease progresses and OFF episodes become more frequent.”

The U.S. Food and Drug Administration approved KYNMOBI on May 21, 2020. Its commercial activities began Sept. 29.